entertainment -WSS

entertainment

author：entertainment 2025-09-02 08:10:16 - browse：17

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FTC sues over Novant Health acquisition of two N.C. hospitals

focus

WSS

Investment in vaccine development is lagging, report finds

FTC sues over Novant Health acquisition of two N.C. hospitals

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

5 dead in mass shooting on Caribbean island of St. Vincent: Police

Humana’s losses in Medicare Advantage tank its stock

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

explore

entertainment

hotspot

Sports medicine is finally prioritizing gender equality

Medicare Advantage insurers face 0.2% cut to 2025 payments

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why Medicare shouldn’t cover every FDA

DIEP, the 'gold standard' of breast reconstruction, is under threat

Merck, Johnson & Johnson CEOs will testify on high drug prices

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Syphilis numbers in the United States reach record heights

Walensky prepares to leave CDC — and Congress — behind

10 reasons why health care startups fail

Wikipedia

Scientists grapple with ethics of stem cell research

How a Boston hospital is priming medical residents to use GPT

Zyn nicotine pouches become unlikely player in latest culture war

Scientists grapple with ethics of stem cell research

Delta passengers in Vegas fall sick while waiting on flight in triple

Syphilis numbers in the United States reach record heights

focus

focus

leisure time

Wikipedia